This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
JAMA Cardiology
DECEMBER 17, 2024
This study assesses the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with heart failure with preserved ejection fraction.
DAIC
MAY 6, 2024
Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Heart BMJ
FEBRUARY 12, 2025
Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype. Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype.
52 
The New England Journal of Medicine
JANUARY 29, 2025
Treatment options for heart failure with preserved ejection fraction have historically been limited. In a 2016 review of this condition in the Journal, treatment recommendations focused on diuretics, exercise training, and management of coexisting conditions.1
American College of Cardiology
JULY 29, 2024
The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).
European Journal of Heart Failure
OCTOBER 30, 2023
ΔPAWP: difference of PAWP between rest and peak exercise. 2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest. 2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest.
JAMA Cardiology
AUGUST 13, 2024
This randomized clinical trial investigates the effects of verinurad on exercise capacity and symptoms in patients with heart failure with preserved ejection fraction (HFpEF) and elevated serum uric acid levels.
JAMA Cardiology
MARCH 11, 2025
This randomized clinical trial evaluates if HU6, a controlled metabolic accelerator, reduces body weight, improves body composition, and increases exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
Circulation
JANUARY 22, 2025
Use of separate rule-in and rule-out diagnostic thresholds stratified by BMI reduces miscategorization and can guide more appropriate use of exercise testing for possible HFpEF. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF.
Circulation: Heart Failure
OCTOBER 23, 2023
BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive. Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023.
Circulation: Heart Failure
DECEMBER 6, 2024
BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life. In heart failure with reduced ejection fraction, exercise stimulates a reflex increase in muscle sympathetic nerve activity (MSNA) that relates inversely to peak oxygen uptake (VO2peak).
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Pulmonary vascular resistance at rest and exercise decreased with higher BMI.
European Journal of Heart Failure
DECEMBER 28, 2023
Abstract Aims Preventive strategies for heart failure (HF) with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. Thus, we evaluated the association between CRF and HFpEF incidence.
Journal of the American Heart Association
DECEMBER 29, 2023
BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. The patients underwent invasive cardiac catheterization and simultaneous echocardiography at rest and during exercise.
Journal of the American Heart Association
FEBRUARY 14, 2024
Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We
DAIC
APRIL 22, 2024
RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF).
Heart BMJ
FEBRUARY 12, 2024
Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heart failure (HF). To understand the key principles of exercise training prescription in people with HF. cross-ref type="bib".
40 
Journal of the American Heart Association
MARCH 3, 2025
Journal of the American Heart Association, Ahead of Print.
Circulation: Heart Failure
DECEMBER 1, 2023
Circulation: Heart Failure, Ahead of Print.
Circulation: Heart Failure
SEPTEMBER 12, 2023
BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. We defined HFpEF based on the presence of elevated left ventricular filling pressures at rest or during exercise. P<0.001).
40 
Circulation: Heart Failure
DECEMBER 18, 2023
mm Hg with exercise (P<0.001). mm Hg with exercise (P<0.001). At peak exercise, RT was responsible for 64% (53%–76%) of end-diastolic pressure, whereas incomplete relaxation and stiffness accounted for the rest. mm Hg in HF with preserved ejection fraction patients and was also exacerbated by exercise.
The American Journal of Cardiology
FEBRUARY 8, 2024
Publication date: Available online 7 February 2024 Source: The American Journal of Cardiology Author(s): Lajjaben Patel, Matthew W Segar, Neil Keshvani, Vinayak Subramanian, Ambarish Pandey, Alvin Chandra
DAIC
APRIL 3, 2024
Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting.
105 
JAMA Cardiology
JULY 23, 2024
Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.
Circulation
NOVEMBER 11, 2024
Introduction:Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure which is rapidly rising in incidence in the US today. After 5 weeks of the diet, HFD mice and their littermate controls underwent baseline exercise testing and echocardiograms.
Circulation
DECEMBER 21, 2023
BACKGROUND:Metabolic distress is often associated with heart failure with preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Circulation, Ahead of Print. Metabolism-induced systemic inflammation links comorbidities with HFpEF.
Circulation
NOVEMBER 11, 2024
Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. HFD/L-NAME mice showed altered exercise capacity (p<0.05
40 
Dr. S. Venkatesan MD
APRIL 18, 2024
It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity. Shah, author of Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial.
DAIC
FEBRUARY 29, 2024
ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)
103 
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
European Journal of Heart Failure
NOVEMBER 19, 2024
Muscle quality and cardiac function in heart failure with preserved ejection fraction (HFpEF) during exercise. Therefore, the study aimed to determine the relationship between locomotor MQ and cardiac function during exercise in HFpEF. MQ was calculated as peak watts divided by LL%. vs. 2.3 ± 0.6 W/%,
European Journal of Heart Failure
DECEMBER 13, 2023
Venn diagram highlighting the main similarities and differences between heart failure with preserved ejection fraction (HFpEF) and aortic stenosis with preserved ejection fraction (ASpEF). This study aimed to provide a non-invasive, comparative analysis of ASpEF versus HFpEF at rest and during exercise.
European Journal of Heart Failure
DECEMBER 7, 2023
ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). There were 94 patients with events over a median follow-up of 2.9 (IQR 2.92, p = 0.01).
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
Circulation
DECEMBER 7, 2023
BACKGROUND:Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction. 95% CI, 0.00, 8.3;P=0.058).
European Journal of Heart Failure
FEBRUARY 5, 2025
Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). However, there is recent concern that this type of medication may be harmful in patients with HFmrEF/HFpEF, causing exercise intolerance possibly due to exacerbation of chronotrophic incompetence.
European Journal of Heart Failure
DECEMBER 29, 2023
Abstract Aims We aim to clarify the extent to which cardiac and peripheral impairments to oxygen delivery and utilization contribute to exercise intolerance and risk for adverse events, and how this relates to diversity and multiplicity in pathophysiological traits. Hemodynamics and oxygen transport responses were compared. L/min versus 2.8
Circulation
NOVEMBER 11, 2024
The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. After controlling for potential confounding variables, there were no differences in baseline exercise capacity [peak VO2 (mL/kg/min): 12.1 Patients were divided into two groups based on BB use at trial enrollment.
Circulation
NOVEMBER 17, 2024
Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. Circulation, Ahead of Print. The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).Conclusions:
Circulation
NOVEMBER 11, 2023
Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight. Circulation, Ahead of Print.
DAIC
JUNE 26, 2024
The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”
DAIC
APRIL 9, 2024
Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The study was funded by Imbria Pharmaceuticals, developer of ninerafaxstat.
International Journal of Cardiovascular Sciences
OCTOBER 21, 2024
Santos Most Cited Article – Reduction in Hospitalization and Increase in Mortality Due to Cardiovascular Diseases during the COVID-19 Pandemic in Brazil Authors: Paulo Garcia Normando, José de Arimatéia Araujo-Filho, Gabriela de Alcântara Fonseca, Rodrigo Elton Ferreira Rodrigues, Victor Agripino Oliveira, Ludhmila Abrahão Hajjar, André Luiz (..)
52 
Cardiometabolic Health Congress
JULY 25, 2023
4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), but also in those with coronary heart disease. [5, Carbone, Salvatore, et al. Future Cardiology 13.5
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content